Share Price and Basic Stock Data
Last Updated: November 16, 2025, 7:31 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Chemiesynth (Vapi) Ltd operates in the organic chemicals sector, focusing on specialty chemicals. The company reported a market capitalization of ₹11.6 Cr, with its stock price currently at ₹37.6. Revenue from operations for the fiscal year ending March 2025 stood at ₹18.89 Cr, which reflects a recovery from ₹16.43 Cr in March 2024, indicating a year-on-year growth trend. Quarterly sales figures show fluctuations, with the highest quarterly sales recorded at ₹7.12 Cr in December 2022, followed by a decline to ₹4.39 Cr in June 2023. The trailing twelve-month (TTM) sales amounted to ₹20.00 Cr, suggesting a potential stabilization in revenue generation. The company has faced significant challenges, as evidenced by a decline in annual sales from ₹30.18 Cr in March 2022 to ₹20.94 Cr in March 2023, indicating a need for strategic operational adjustments to enhance revenue stability.
Profitability and Efficiency Metrics
The profitability of Chemiesynth (Vapi) Ltd has shown considerable volatility. The operating profit margin (OPM) for March 2025 stood at 12.13%, an improvement from 11.70% in the previous year, suggesting enhanced operational efficiency. However, the company reported a net profit of ₹-0.11 Cr for the fiscal year ending March 2025, down from ₹0.56 Cr in March 2023, reflecting ongoing profitability challenges. The interest coverage ratio (ICR) was reported at 2.75x, indicating that the company has a reasonable ability to meet its interest obligations. However, its return on equity (ROE) has been low, recorded at 0.99% for the current fiscal year, which is significantly below typical industry averages. The cash conversion cycle (CCC) of 21.04 days is commendable, reflecting efficient management of working capital compared to industry norms. Overall, while there are indicators of improving profitability, significant risks remain in achieving consistent net profitability.
Balance Sheet Strength and Financial Ratios
Chemiesynth (Vapi) Ltd’s balance sheet reveals a concerning lack of reserves and borrowings, both reported as not available. This absence raises questions about financial stability and the company’s ability to fund future growth initiatives. The total debt to equity ratio stood at 1.37, indicating a relatively high level of leverage, which can pose risks should market conditions worsen. The company’s book value per share was reported at ₹35.77, demonstrating a solid asset base relative to its market price. However, the current ratio of 0.46 indicates potential liquidity issues, as it falls below the ideal threshold of 1, suggesting that current liabilities exceed current assets. The inventory turnover ratio of 1.08x reflects inefficiencies in managing inventory, as it is below the typical industry standard. These financial ratios highlight the need for Chemiesynth to improve its financial management practices to bolster balance sheet strength and operational resilience.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Chemiesynth (Vapi) Ltd indicates a strong promoter presence, with promoters holding 62.35% of the equity, reflecting confidence in the management’s vision and strategy. The public shareholding stands at 37.66%, which is relatively stable, with the total number of shareholders recorded at 524. This stability in shareholding can be a positive sign for potential investors, as it suggests that the company is not facing significant selling pressure from its public investors. However, the absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) may indicate a lack of broader market interest, which could limit stock liquidity and price appreciation potential. The consistent promoter holding over recent quarters also suggests a commitment to long-term value creation, which is crucial for maintaining investor confidence amidst operational challenges.
Outlook, Risks, and Final Insight
The outlook for Chemiesynth (Vapi) Ltd is mixed, with potential for recovery in revenue and profitability but significant risks associated with financial management and market conditions. The company’s ability to enhance its operational efficiency and manage costs effectively will be critical in achieving sustainable profitability. Risks include the high level of debt relative to equity, which could strain financial resources during downturns, and the current liquidity ratios that suggest possible funding challenges. Furthermore, the volatile revenue trends necessitate strategic initiatives to stabilize income streams and improve profitability margins. If the company can successfully navigate these challenges, it may position itself for a more favorable operational environment, leading to enhanced shareholder value. Conversely, failure to address these issues could result in further financial deterioration and diminished investor confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Chemiesynth (Vapi) Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Gujchem Distillers India Ltd | 109 Cr. | 306 | 456/255 | 254 | 392 | 0.04 % | 0.21 % | 0.09 % | 1.00 |
| Elantas Beck India Ltd | 7,690 Cr. | 9,700 | 14,250/8,150 | 55.7 | 1,177 | 0.08 % | 23.0 % | 17.4 % | 10.0 |
| Crestchem Ltd | 36.2 Cr. | 121 | 329/109 | 17.9 | 26.9 | 0.83 % | 59.9 % | 44.1 % | 10.0 |
| Chemiesynth (Vapi) Ltd | 11.6 Cr. | 37.6 | 37.6/35.8 | 32.8 | 0.00 % | 3.10 % | 0.99 % | 10.0 | |
| ARCL Organics Ltd | 302 Cr. | 378 | 435/163 | 16.8 | 108 | 0.00 % | 20.4 % | 16.8 % | 10.0 |
| Industry Average | 4,498.69 Cr | 1,592.05 | 67.41 | 334.84 | 0.40% | 14.71% | 10.69% | 7.56 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4.54 | 4.43 | 7.12 | 4.85 | 4.39 | 4.37 | 3.22 | 4.45 | 2.85 | 5.47 | 3.88 | 6.68 |
| Expenses | 4.76 | 3.94 | 5.78 | 3.89 | 4.48 | 3.00 | 3.31 | 4.10 | 2.66 | 4.51 | 3.65 | 5.87 |
| Operating Profit | -0.22 | 0.49 | 1.34 | 0.96 | -0.09 | 1.37 | -0.09 | 0.35 | 0.19 | 0.96 | 0.23 | 0.81 |
| OPM % | -4.85% | 11.06% | 18.82% | 19.79% | -2.05% | 31.35% | -2.80% | 7.87% | 6.67% | 17.55% | 5.93% | 12.13% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 |
| Interest | 0.11 | 0.16 | 0.15 | 0.16 | 0.12 | 0.21 | 0.11 | 0.26 | 0.09 | 0.17 | 0.34 | 0.20 |
| Depreciation | 0.27 | 0.27 | 0.30 | 0.33 | 0.30 | 0.32 | 0.32 | 0.36 | 0.34 | 0.38 | 0.36 | 0.33 |
| Profit before tax | -0.60 | 0.06 | 0.89 | 0.47 | -0.51 | 0.84 | -0.52 | -0.26 | -0.24 | 0.41 | -0.47 | 0.29 |
| Tax % | 0.00% | 0.00% | 5.62% | 44.68% | 0.00% | 0.00% | 0.00% | -23.08% | 0.00% | 0.00% | 0.00% | 34.48% |
| Net Profit | -0.61 | 0.06 | 0.84 | 0.26 | -0.51 | 0.85 | -0.52 | -0.20 | -0.24 | 0.42 | -0.47 | 0.19 |
| EPS in Rs | -1.99 | 0.20 | 2.74 | 0.85 | -1.66 | 2.77 | -1.69 | -0.65 | -0.78 | 1.37 | -1.53 | 0.62 |
Last Updated: May 31, 2025, 6:32 am
Below is a detailed analysis of the quarterly data for Chemiesynth (Vapi) Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 6.68 Cr.. The value appears strong and on an upward trend. It has increased from 3.88 Cr. (Dec 2024) to 6.68 Cr., marking an increase of 2.80 Cr..
- For Expenses, as of Mar 2025, the value is 5.87 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.65 Cr. (Dec 2024) to 5.87 Cr., marking an increase of 2.22 Cr..
- For Operating Profit, as of Mar 2025, the value is 0.81 Cr.. The value appears strong and on an upward trend. It has increased from 0.23 Cr. (Dec 2024) to 0.81 Cr., marking an increase of 0.58 Cr..
- For OPM %, as of Mar 2025, the value is 12.13%. The value appears strong and on an upward trend. It has increased from 5.93% (Dec 2024) to 12.13%, marking an increase of 6.20%.
- For Other Income, as of Mar 2025, the value is 0.01 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Dec 2024) to 0.01 Cr., marking an increase of 0.01 Cr..
- For Interest, as of Mar 2025, the value is 0.20 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.34 Cr. (Dec 2024) to 0.20 Cr., marking a decrease of 0.14 Cr..
- For Depreciation, as of Mar 2025, the value is 0.33 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.36 Cr. (Dec 2024) to 0.33 Cr., marking a decrease of 0.03 Cr..
- For Profit before tax, as of Mar 2025, the value is 0.29 Cr.. The value appears strong and on an upward trend. It has increased from -0.47 Cr. (Dec 2024) to 0.29 Cr., marking an increase of 0.76 Cr..
- For Tax %, as of Mar 2025, the value is 34.48%. The value appears to be increasing, which may not be favorable. It has increased from 0.00% (Dec 2024) to 34.48%, marking an increase of 34.48%.
- For Net Profit, as of Mar 2025, the value is 0.19 Cr.. The value appears strong and on an upward trend. It has increased from -0.47 Cr. (Dec 2024) to 0.19 Cr., marking an increase of 0.66 Cr..
- For EPS in Rs, as of Mar 2025, the value is 0.62. The value appears strong and on an upward trend. It has increased from -1.53 (Dec 2024) to 0.62, marking an increase of 2.15.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:40 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 9.63 | 11.13 | 5.12 | 3.09 | 13.32 | 11.20 | 14.56 | 19.90 | 30.18 | 20.94 | 16.43 | 18.89 | 20.00 |
| Expenses | 9.10 | 11.55 | 5.26 | 3.17 | 12.67 | 9.26 | 12.27 | 14.32 | 25.71 | 18.37 | 14.88 | 16.68 | 17.82 |
| Operating Profit | 0.53 | -0.42 | -0.14 | -0.08 | 0.65 | 1.94 | 2.29 | 5.58 | 4.47 | 2.57 | 1.55 | 2.21 | 2.18 |
| OPM % | 5.50% | -3.77% | -2.73% | -2.59% | 4.88% | 17.32% | 15.73% | 28.04% | 14.81% | 12.27% | 9.43% | 11.70% | 10.90% |
| Other Income | 0.13 | 0.02 | 0.03 | 0.27 | 0.46 | 0.06 | 0.12 | 0.02 | 0.94 | 0.00 | 0.01 | 0.01 | 0.01 |
| Interest | 0.30 | 0.29 | 0.23 | 0.19 | 0.19 | 0.09 | 0.28 | 0.48 | 0.50 | 0.59 | 0.71 | 0.83 | 0.96 |
| Depreciation | 0.25 | 0.28 | 0.20 | 0.18 | 0.52 | 0.46 | 0.55 | 0.78 | 1.05 | 1.17 | 1.30 | 1.40 | 1.46 |
| Profit before tax | 0.11 | -0.97 | -0.54 | -0.18 | 0.40 | 1.45 | 1.58 | 4.34 | 3.86 | 0.81 | -0.45 | -0.01 | -0.23 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 19.31% | 17.09% | 17.74% | 29.79% | 32.10% | -13.33% | 1,000.00% | |
| Net Profit | 0.11 | -0.97 | -0.54 | -0.18 | 0.39 | 1.17 | 1.31 | 3.56 | 2.72 | 0.56 | -0.39 | -0.11 | -0.32 |
| EPS in Rs | 0.36 | -3.16 | -1.76 | -0.59 | 1.27 | 3.81 | 4.27 | 11.60 | 8.86 | 1.82 | -1.27 | -0.36 | -1.04 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -981.82% | 44.33% | 66.67% | 316.67% | 200.00% | 11.97% | 171.76% | -23.60% | -79.41% | -169.64% | 71.79% |
| Change in YoY Net Profit Growth (%) | 0.00% | 1026.15% | 22.34% | 250.00% | -116.67% | -188.03% | 159.79% | -195.35% | -55.82% | -90.23% | 241.44% |
Chemiesynth (Vapi) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 5% |
| 3 Years: | -14% |
| TTM: | 34% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -191% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 11% |
| 3 Years: | 0% |
| Last Year: | -1% |
Last Updated: September 5, 2025, 2:56 pm
No data available for the Balance Sheet data table.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 12.51 | 26.89 | 31.37 | 24.81 | 27.13 | 55.08 | 39.86 | 67.86 | 41.60 | 47.24 | 47.10 | 55.07 |
| Inventory Days | 126.69 | 44.60 | 136.35 | 580.41 | 16.18 | 231.23 | 217.06 | 165.17 | 80.99 | 200.09 | 386.19 | 167.61 |
| Days Payable | 156.86 | 126.75 | 159.43 | 741.97 | 43.60 | 605.79 | 366.21 | 695.35 | 159.36 | 200.78 | 111.85 | 201.64 |
| Cash Conversion Cycle | -17.66 | -55.26 | 8.29 | -136.75 | -0.29 | -319.48 | -109.29 | -462.31 | -36.77 | 46.55 | 321.44 | 21.04 |
| Working Capital Days | -48.89 | -53.78 | -47.76 | -103.95 | -9.04 | -28.68 | -60.92 | -65.85 | -49.83 | -65.89 | -105.08 | -122.12 |
| ROCE % | 3.04% | -6.90% | -3.21% | -2.44% | 5.28% | 13.73% | 13.89% | 28.39% | 16.35% | 5.82% | 1.00% | 3.10% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -0.35 | -1.26 | 1.81 | 8.85 | 11.60 |
| Diluted EPS (Rs.) | -0.35 | -1.26 | 1.81 | 8.85 | 11.60 |
| Cash EPS (Rs.) | 4.22 | 2.97 | 5.61 | 12.28 | 14.14 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 35.77 | 36.94 | 38.20 | 36.39 | 27.55 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 35.77 | 36.94 | 38.20 | 36.39 | 27.55 |
| Revenue From Operations / Share (Rs.) | 61.52 | 53.53 | 68.21 | 98.32 | 64.81 |
| PBDIT / Share (Rs.) | 7.14 | 5.04 | 8.34 | 14.58 | 18.03 |
| PBIT / Share (Rs.) | 2.57 | 0.80 | 4.54 | 11.15 | 15.49 |
| PBT / Share (Rs.) | -0.02 | -1.47 | 2.65 | 12.57 | 14.12 |
| Net Profit / Share (Rs.) | -0.34 | -1.26 | 1.81 | 8.85 | 11.60 |
| PBDIT Margin (%) | 11.60 | 9.41 | 12.22 | 14.83 | 27.82 |
| PBIT Margin (%) | 4.18 | 1.50 | 6.65 | 11.33 | 23.90 |
| PBT Margin (%) | -0.04 | -2.74 | 3.88 | 12.78 | 21.78 |
| Net Profit Margin (%) | -0.56 | -2.36 | 2.65 | 8.99 | 17.89 |
| Return on Networth / Equity (%) | -0.96 | -3.42 | 4.73 | 24.30 | 42.11 |
| Return on Capital Employeed (%) | 3.87 | 1.16 | 6.50 | 17.22 | 26.86 |
| Return On Assets (%) | -0.32 | -1.23 | 1.79 | 9.16 | 13.25 |
| Long Term Debt / Equity (X) | 0.73 | 0.75 | 0.71 | 0.67 | 1.07 |
| Total Debt / Equity (X) | 1.37 | 1.37 | 1.16 | 1.04 | 1.28 |
| Asset Turnover Ratio (%) | 0.59 | 0.52 | 0.69 | 1.07 | 0.89 |
| Current Ratio (X) | 0.46 | 0.53 | 0.60 | 0.68 | 0.65 |
| Quick Ratio (X) | 0.30 | 0.21 | 0.30 | 0.45 | 0.49 |
| Inventory Turnover Ratio (X) | 1.08 | 1.11 | 2.48 | 5.82 | 2.02 |
| Interest Coverage Ratio (X) | 2.75 | 2.22 | 4.41 | 9.33 | 13.16 |
| Interest Coverage Ratio (Post Tax) (X) | 0.86 | 0.44 | 1.96 | 4.75 | 9.46 |
| Enterprise Value (Cr.) | 25.47 | 23.72 | 19.75 | 16.16 | 0.00 |
| EV / Net Operating Revenue (X) | 1.35 | 1.44 | 0.94 | 0.53 | 0.00 |
| EV / EBITDA (X) | 11.62 | 15.33 | 7.71 | 3.61 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 0.55 | 0.50 | 0.29 | 0.18 | 0.00 |
| Price / BV (X) | 0.95 | 0.72 | 0.52 | 0.49 | 0.00 |
| Price / Net Operating Revenue (X) | 0.55 | 0.50 | 0.29 | 0.18 | 0.00 |
| EarningsYield | -0.01 | -0.04 | 0.09 | 0.48 | 0.00 |
After reviewing the key financial ratios for Chemiesynth (Vapi) Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -0.35. This value is below the healthy minimum of 5. It has increased from -1.26 (Mar 24) to -0.35, marking an increase of 0.91.
- For Diluted EPS (Rs.), as of Mar 25, the value is -0.35. This value is below the healthy minimum of 5. It has increased from -1.26 (Mar 24) to -0.35, marking an increase of 0.91.
- For Cash EPS (Rs.), as of Mar 25, the value is 4.22. This value is within the healthy range. It has increased from 2.97 (Mar 24) to 4.22, marking an increase of 1.25.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 35.77. It has decreased from 36.94 (Mar 24) to 35.77, marking a decrease of 1.17.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 35.77. It has decreased from 36.94 (Mar 24) to 35.77, marking a decrease of 1.17.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 61.52. It has increased from 53.53 (Mar 24) to 61.52, marking an increase of 7.99.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 7.14. This value is within the healthy range. It has increased from 5.04 (Mar 24) to 7.14, marking an increase of 2.10.
- For PBIT / Share (Rs.), as of Mar 25, the value is 2.57. This value is within the healthy range. It has increased from 0.80 (Mar 24) to 2.57, marking an increase of 1.77.
- For PBT / Share (Rs.), as of Mar 25, the value is -0.02. This value is below the healthy minimum of 0. It has increased from -1.47 (Mar 24) to -0.02, marking an increase of 1.45.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -0.34. This value is below the healthy minimum of 2. It has increased from -1.26 (Mar 24) to -0.34, marking an increase of 0.92.
- For PBDIT Margin (%), as of Mar 25, the value is 11.60. This value is within the healthy range. It has increased from 9.41 (Mar 24) to 11.60, marking an increase of 2.19.
- For PBIT Margin (%), as of Mar 25, the value is 4.18. This value is below the healthy minimum of 10. It has increased from 1.50 (Mar 24) to 4.18, marking an increase of 2.68.
- For PBT Margin (%), as of Mar 25, the value is -0.04. This value is below the healthy minimum of 10. It has increased from -2.74 (Mar 24) to -0.04, marking an increase of 2.70.
- For Net Profit Margin (%), as of Mar 25, the value is -0.56. This value is below the healthy minimum of 5. It has increased from -2.36 (Mar 24) to -0.56, marking an increase of 1.80.
- For Return on Networth / Equity (%), as of Mar 25, the value is -0.96. This value is below the healthy minimum of 15. It has increased from -3.42 (Mar 24) to -0.96, marking an increase of 2.46.
- For Return on Capital Employeed (%), as of Mar 25, the value is 3.87. This value is below the healthy minimum of 10. It has increased from 1.16 (Mar 24) to 3.87, marking an increase of 2.71.
- For Return On Assets (%), as of Mar 25, the value is -0.32. This value is below the healthy minimum of 5. It has increased from -1.23 (Mar 24) to -0.32, marking an increase of 0.91.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.73. This value is within the healthy range. It has decreased from 0.75 (Mar 24) to 0.73, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.37. This value exceeds the healthy maximum of 1. There is no change compared to the previous period (Mar 24) which recorded 1.37.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.59. It has increased from 0.52 (Mar 24) to 0.59, marking an increase of 0.07.
- For Current Ratio (X), as of Mar 25, the value is 0.46. This value is below the healthy minimum of 1.5. It has decreased from 0.53 (Mar 24) to 0.46, marking a decrease of 0.07.
- For Quick Ratio (X), as of Mar 25, the value is 0.30. This value is below the healthy minimum of 1. It has increased from 0.21 (Mar 24) to 0.30, marking an increase of 0.09.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.08. This value is below the healthy minimum of 4. It has decreased from 1.11 (Mar 24) to 1.08, marking a decrease of 0.03.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.75. This value is below the healthy minimum of 3. It has increased from 2.22 (Mar 24) to 2.75, marking an increase of 0.53.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.86. This value is below the healthy minimum of 3. It has increased from 0.44 (Mar 24) to 0.86, marking an increase of 0.42.
- For Enterprise Value (Cr.), as of Mar 25, the value is 25.47. It has increased from 23.72 (Mar 24) to 25.47, marking an increase of 1.75.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.35. This value is within the healthy range. It has decreased from 1.44 (Mar 24) to 1.35, marking a decrease of 0.09.
- For EV / EBITDA (X), as of Mar 25, the value is 11.62. This value is within the healthy range. It has decreased from 15.33 (Mar 24) to 11.62, marking a decrease of 3.71.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.55. This value is below the healthy minimum of 1. It has increased from 0.50 (Mar 24) to 0.55, marking an increase of 0.05.
- For Price / BV (X), as of Mar 25, the value is 0.95. This value is below the healthy minimum of 1. It has increased from 0.72 (Mar 24) to 0.95, marking an increase of 0.23.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.55. This value is below the healthy minimum of 1. It has increased from 0.50 (Mar 24) to 0.55, marking an increase of 0.05.
- For EarningsYield, as of Mar 25, the value is -0.01. This value is below the healthy minimum of 5. It has increased from -0.04 (Mar 24) to -0.01, marking an increase of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Chemiesynth (Vapi) Ltd:
- Net Profit Margin: -0.56%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 3.87% (Industry Average ROCE: 14.71%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -0.96% (Industry Average ROE: 10.69%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0.86
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.3
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 67.41)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.37
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -0.56%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Organic - Others | Plot No 27, GIDC, Vapi, Valsad District Gujarat 396195 | csl@chemiesynth.com http://www.chemiesynth.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sandip Satishbhai Zaveri | Managing Director |
| Mr. Satish Bhogilal Zaveri | Non Exe.Non Ind.Director |
| Mr. Bhanurai Nagindas Mehta | Non Exe.Non Ind.Director |
| Mr. Rushabh Suresh Mehta | Non Exe.Non Ind.Director |
| Mrs. Jigna Prajapati | Independent Woman Director |
| Mr. Pramod Gopaldas Gujarathi | Independent Director |